These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 7025255)

  • 21. Effect of prostaglandin I2 and analogs on platelet aggregation and smooth muscle contraction.
    Crane BH; Maish TL; Maddox YT; Corey EJ; Székely I; Ramwell PW
    J Pharmacol Exp Ther; 1978 Jul; 206(1):132-8. PubMed ID: 351171
    [No Abstract]   [Full Text] [Related]  

  • 22. Thromboxane synthetase inhibition results in increased platelet sensitivity to prostacyclin.
    Bertelé V; Falanga A; Roncaglioni MC; Cerletti C; de Gaetano G
    Thromb Haemost; 1982 Jun; 47(3):294. PubMed ID: 7051411
    [No Abstract]   [Full Text] [Related]  

  • 23. Evaluation of prostaglandin and prostacyclin antagonism at platelet receptors by aggregometry.
    Eggerman TL; Harker LA; Andersen NH; Wilson CH
    Adv Prostaglandin Thromboxane Res; 1980; 6():389-93. PubMed ID: 6247888
    [No Abstract]   [Full Text] [Related]  

  • 24. The effect of prostacyclin on platelet aggregation and disaggregation in vivo.
    Martin JF; Suggett AJ; Leach E; Moncada S
    Thromb Res; 1980 Jun; 18(5):749-51. PubMed ID: 6998043
    [No Abstract]   [Full Text] [Related]  

  • 25. The role of prostacyclin in vascular tissue.
    Moncada S; Vane JR
    Fed Proc; 1979 Jan; 38(1):66-71. PubMed ID: 215463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of prostacyclin, 6-keto-PGF1 alpha PGF2 alpha and 15[S]15-methyl-PGF2 alpha on platelet aggregation in vitro.
    Marmo E; Somma A; Ottavo R; Vairo G; Spaziante G; DiMezza F; Paone G
    J Med; 1981; 12(2-3):97-108. PubMed ID: 7024451
    [No Abstract]   [Full Text] [Related]  

  • 27. Modified sensitivity of diabetic platelets to prostacyclin.
    Bonne C; Romquin N; Regnault F
    Bibl Anat; 1979; (18):98-103. PubMed ID: 227357
    [No Abstract]   [Full Text] [Related]  

  • 28. Reversal of platelet aggregation by prostacyclin.
    Gryglewski RJ; Korbut R; Ocetkiewicz A
    Pharmacol Res Commun; 1978 Feb; 10(2):185-9. PubMed ID: 349573
    [No Abstract]   [Full Text] [Related]  

  • 29. A prospective method for thrombotic diseases using prostaglandin I2.
    Isobe J; Mizuno A
    Tokushima J Exp Med; 1982 Jun; 29(1-2):95-101. PubMed ID: 6755803
    [No Abstract]   [Full Text] [Related]  

  • 30. In vitro inhibition by endotoxin of the anti-aggregatory action of prostacyclin produced by aortic rings.
    Bult H; Herman AG
    Arch Int Pharmacodyn Ther; 1978 Aug; 234(2):335-6. PubMed ID: 361006
    [No Abstract]   [Full Text] [Related]  

  • 31. [Prostacyclin--a new biologically active agent].
    Vapaatalo H
    Duodecim; 1980; 96(3):175-80. PubMed ID: 7004837
    [No Abstract]   [Full Text] [Related]  

  • 32. 20-Methylprostacyclin: a powerful 'unnatural' platelet aggregation inhibitor.
    van Dorp DA; van Evert WC; van der Wolf L
    Prostaglandins; 1978 Dec; 16(6):953-5. PubMed ID: 373021
    [No Abstract]   [Full Text] [Related]  

  • 33. Prostacyclin and the vascular endothelium.
    Moncada S; Vane JR
    Bull Eur Physiopathol Respir; 1981; 17(4):687-701. PubMed ID: 7034824
    [No Abstract]   [Full Text] [Related]  

  • 34. [Platelet sensitivity to prostacyclin (PGI2) in patients with juvenile-onset diabetes mellitus (author's transl)].
    Klein K; Sinzinger H; Schernthaner G; Silberbauer K; Prager R
    Wien Klin Wochenschr; 1981 Jul; 93(14):460-2. PubMed ID: 7023074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Difficulty in detecting inhibition of platelet aggregation by the impedance method.
    Ingerman-Wojenski CM; Smith JB; Silver MJ
    Thromb Res; 1982 Nov; 28(3):427-32. PubMed ID: 6758188
    [No Abstract]   [Full Text] [Related]  

  • 36. Preservation of platelet function and number by prostacyclin during cardiopulmonary bypass.
    Coppe D; Sobel M; Seamans L; Levine F; Salzman E
    J Thorac Cardiovasc Surg; 1981 Feb; 81(2):274-8. PubMed ID: 7005550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of PGI2 and di-butyryl cyclic-AMP on platelets exposed to shear stress.
    Hardwick RA; Hellums JD; Peterson DM; Moake J; Olson J
    Trans Am Soc Artif Intern Organs; 1981; 27():192-6. PubMed ID: 6277071
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of the vascular responses to various prostanoic compounds in the puppy and adult dog.
    Fitzpatrick T; Harris R; Ramwell P; Kot P
    Adv Prostaglandin Thromboxane Res; 1980; 7():727-9. PubMed ID: 6989200
    [No Abstract]   [Full Text] [Related]  

  • 39. Extremely-low-dose aspirin (1 mg per day) renders human platelets more sensitive to antiaggregation prostaglandins.
    Sinzinger H; O'Grady J; Fitscha P; Kaliman J
    N Engl J Med; 1984 Oct; 311(16):1052. PubMed ID: 6384781
    [No Abstract]   [Full Text] [Related]  

  • 40. Application of a new prostaglandin I2 analogue (APS-306) on cardiopulmonary bypass.
    Takahama T; Kanai F; Iizuka I; Hiraishi M; Yamazaki Z; Idezuki Y; Sudo K; Asano K; Morioka M; Kazama M
    Trans Am Soc Artif Intern Organs; 1984; 30():44-8. PubMed ID: 6398549
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.